
CITATION REPORT List of articles citing



DOI: 10.2147/vhrm.2006.2.4.411 Vascular Health and Risk Management, 2006, 2, 411-22.

Source: https://exaly.com/paper-pdf/88098772/citation-report.pdf

Version: 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
106	Pathogenic mechanisms of pulmonary arterial hypertension. 2008 , 44, 14-30		195
105	Treatment of pediatric pulmonary hypertension. Vascular Health and Risk Management, 2009, 5, 509-24	4.4	17
104	Atherosclerosis in sickle cell disease - a review. 2009 , 18, 62-6		17
103	Pulmonary hypertension in thoracic surgical patients. 2010 , 23, 25-33		18
102	Pulmonary vascular disease related to hemodynamic stress in the pulmonary circulation. 2011 , 1, 123-3	9	3
101	Sildenafil inhibits chronically hypoxic upregulation of canonical transient receptor potential expression in rat pulmonary arterial smooth muscle. 2010 , 298, C114-23		51
100	Regulation of cardiovascular TRP channel functions along the NO-cGMP-PKG axis. 2010 , 3, 347-60		4
99	Intravenous sildenafil for postoperative pulmonary hypertension in children with congenital heart disease. 2011 , 37, 502-9		63
98	Predictors of postoperative outcome after pulmonary endarterectomy from a 14-year experience with 279 patients. 2011 , 40, 154-61		30
97	Medication Repurposing: New Uses for Old Drugs. 2011 , 27, 132-140		5
96	Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions. 2011 , 91, 651-90		443
95	Pulmonary hypertension associated with left-sided heart disease. 2012 , 8, 447-59		24
94	Identification of inflammatory mediators and their modulation by strategies for the management of the systemic inflammatory response during cardiac surgery. 2013 , 27, 983-1033		52
93	Salt and cocrystals of sildenafil with dicarboxylic acids: solubility and pharmacokinetic advantage of the glutarate salt. 2013 , 10, 4687-97		105
92	Human immunodeficiency virus-associated pulmonary arterial hypertension. 2013 , 34, 283-92		26
91	Development and stability assessment of liquid paediatric formulations containing sildenafil citrate. 2013 , 49, 381-388		3
90	Combination of sildenafil and bosentan for pulmonary hypertension in a human ex vivo model. 2014 , 28, 45-51		4

(2017-2014)

89	Pharmacological evidence for the participation of NO-cGMP-KATP pathway in the gastric protective effect of curcumin against indomethacin-induced gastric injury in the rat. 2014 , 730, 102-6	19
88	Synthesis and preliminary biological evaluation of potent and selective 2-(3-alkoxy-1-azetidinyl) quinolines as novel PDE10A inhibitors with improved solubility. 2014 , 22, 6570-6585	14
87	Pulmonary hypertension in non-transfusion-dependent thalassemia: Correlation with clinical parameters, liver iron concentration, and non-transferrin-bound iron. 2015 , 20, 610-7	9
86	Vasculopathy and pulmonary hypertension in sickle cell disease. 2015 , 308, L314-24	90
85	Comparison of Neuroprotective Effect of Bevacizumab and Sildenafil following Induction of Stroke in a Mouse Model. 2016 , 2016, 3938523	7
84	An opportunistic study evaluating pharmacokinetics of sildenafil for the treatment of pulmonary hypertension in infants. 2016 , 36, 744-7	11
83	Recent successes and future predictions on drug repurposing for rare diseases. 2016 , 4, 1-4	12
82	Drugs for Treatment of Erectile Dysfunction. 2016 , 783-800	
81	Superior vasodilation of human pulmonary vessels by vardenafil compared with tadalafil and sildenafil: additive effects of bosentan. 2017 , 25, 254-259	7
80	BMP type II receptor as a therapeutic target in pulmonary arterial hypertension. 2017 , 74, 2979-2995	54
79	RP5063, a novel, multimodal, serotonin receptor modulator, prevents Sugen 5416-hypoxia-induced pulmonary arterial hypertension in rats. 2017 , 810, 83-91	9
78	Nebulized solid lipid nanoparticles for the potential treatment of pulmonary hypertension via targeted delivery of phosphodiesterase-5-inhibitor. 2017 , 517, 312-321	44
77	Adsorption and inhibitive properties of sildenafil (Viagra) for zinc in hydrochloric acid solution. 2017 , 7, 3408-3418	5
76	Current and future antenatal management of isolated congenital diaphragmatic hernia. 2017 , 22, 383-390	22
75	Enabling Precision Cardiology Through Multiscale Biology and Systems Medicine. 2017 , 2, 311-327	42
74	Riociguat for patients with chronic thromboembolic pulmonary hypertension: Usefulness of transitioning from phosphodiesterase type 5 inhibitor. 2017 , 55, 270-275	12
73	Management of Sepsis in Patients with Pulmonary Arterial Hypertension in the Intensive Care Unit. 2017 , 29, 15-23	О
72	Preoperative Evaluation of the Cancer Patient for Emergency Surgery. 2017, 1-18	

71	Pulmonary Complications of Liver Cirrhosis: A Concise Review. 2017,	1
70	The impact of polymers on 3D microstructure and controlled release of sildenafil citrate from hydrophilic matrices. 2018 , 119, 234-243	4
69	Evaluation of the effects of RP5063, a novel, multimodal, serotonin receptor modulator, as single-agent therapy and co-administrated with sildenafil, bosentan, and treprostinil in a monocrotaline-induced pulmonary arterial hypertension rat model. 2018 , 827, 159-166	5
68	Drug repositioning: current approaches and their implications in the precision medicine era. 2018 , 3, 49-61	33
67	Ivy and Licorice Triterpene Glycosides: Promising Molecular Containers for Some Drugs and Biomolecules. 2018 , 351-383	4
66	Mixing the Old with the New: Drug Repurposing for Immune Deficiency in the Era of Precision Medicine and Pediatric Genomics. 2018 , 6, 2168-2169	
65	Combined Virtual/Experimental Multicomponent Solid Forms Screening of Sildenafil: New Salts, Cocrystals, and Hybrid Salt¶ocrystals. 2018 , 18, 7618-7627	23
64	The eye in CHD. 2018 , 28, 981-985	3
63	Polymorphism of Sildenafil: A New Metastable Desolvate. 2018 , 18, 3740-3746	13
62	Childhood Pulmonary Arterial Hypertension. 2019 , 556-579.e4	
61	Congenital Diaphragmatic Hernia: In Utero Treatment Today and Tomorrow. 2019, 503-511	
60	Sildenafil does not improve performance in 16.1 km cycle exercise time-trial in acute hypoxia. 2019 , 14, e0210841	5
59	Sildenafil Prevents Marfan-Associated Emphysema and Early Pulmonary Artery Dilation in Mice. 2019 , 189, 1536-1546	3
58	Challenges in pulmonary hypertension associated with left heart disease. 2019 , 17, 461-472	1
57	Pulmonary Hypertension in HIV. 2019 , 35, 288-298	14
56	Design and evaluation of novel inhalable sildenafil citrate spray-dried microparticles for pulmonary arterial hypertension. 2019 , 302, 126-139	29
55	Sildenafil does not reliably improve exercise performance in hypoxia: a systematic review. 2019 , 5, e000526	2
54	Prenatal diagnosis and management of congenital diaphragmatic hernia. 2019 , 58, 93-106	16

53	Formulation and evaluation of carrier-free dry powder inhaler containing sildenafil. 2019, 9, 319-333	7
52	Basic and translational science advances in congenital diaphragmatic hernia. 2020 , 44, 151170	8
51	Multiplicity of Nitric Oxide and Natriuretic Peptide Signaling in Heart Failure. 2020, 75, 370-384	8
50	COVID-19 as a viral functional ACE2 deficiency disorder with ACE2 related multi-organ disease. 2020 , 144, 110024	36
49	Molecularly imprinted sol-gel electrochemical sensor for sildenafil based on alpencil graphite electrode modified by Preyssler heteropolyacid/gold nanoparticles/MWCNT nanocomposite. 2020 , 187, 512	10
48	Behavioral and hormonal effects of prolonged Sildenafil treatment in a mouse model of chronic social stress. 2020 , 392, 112707	
47	Management of Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis. 2020, 13, 15-29	13
46	Spotlight Commentary: Importance of dose redefining in the process of drug repurposing. 2021 , 87, 1705-1707	O
45	Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial. 2021 , 9, 85-95	33
44	Effectiveness of Sildenafil in Pulmonary Hypertension Secondary to Valvular Heart Disease: A Systematic Review and Meta-Analysis. 2021 , 12, 55-65	O
43	Management of kyphoscoliotic pregnant patient presenting with impending respiratory failure 🛭 case report. 2021 , 11, 112	
42	Metabolic -Dealkylation and -Oxidation as Elucidators of the Role of Alkylamino Moieties in Drugs Acting at Various Receptors. 2021 , 26,	1
41	Sildenafil: From angina to SARS-CoV-2. 2021 ,	
40	Sildenafil Counteracts the In Vitro Activation of CXCL-9, CXCL-10 and CXCL-11/CXCR3 Axis Induced by Reactive Oxygen Species in Scleroderma Fibroblasts. 2021 , 10,	2
39	RP5063, a novel, multimodal, serotonin receptor modulator, prevents monocrotaline-induced pulmonary arterial hypertension in rats. 2017 , 810, 92-99	13
38	Sidenafil pre-treatment promotes decompression sickness in rats. 2013 , 8, e60639	16
37	Synergistic interaction between a PDE5 inhibitor (sildenafil) and a new adenosine A2A receptor agonist (LASSBio-1359) improves pulmonary hypertension in rats. 2018 , 13, e0195047	7
36	In Silico studies of novel Sildenafil self-emulsifying drug delivery system absorption improvement for pulmonary arterial hypertension. 2020 , 92, e20191445	1

35	Intraoperative Management of Patients with Pulmonary Hypertension. 2013, 12, 18-23	5
34	The Thiol-polyamine Metabolism of Trypanosoma cruzi: Molecular Targets and Drug Repurposing Strategies. 2019 , 26, 6614-6635	13
33	Sildenafil for Antenatal Treatment of Congenital Diaphragmatic Hernia: From Bench to Bedside. 2019 , 25, 601-608	9
32	Drug Repositioning for COVID-19. 2020 , 51, e4279	3
31	Mitigation of indomethacin-induced gastric mucosal lesions by a potent specific type V phosphodiesterase inhibitor. 2009 , 15, 5091-6	11
30	Does intravenous sildenafil clinically ameliorate pulmonary hypertension during perioperative management of congenital heart diseases in children? - a prospective randomized study. 2015 , 18, 510-6	9
29	Large Atrial Septal Defect Closure in a Patient with Severe Pulmonary Arterial Hypertension. 2017 , 50, 378-381	6
28	Primary Myelofibrosis (PMF) [Previously Chronic Idiopathic Myelofibrosid (CIMF), Myelofibrosis with Myeloid Metaplasia (MMM), Agnogenic Myeloid Metaplasia (AMM)]. 2010 , 81-116	
27	Endothelial Regulation of Pulmonary Vascular Tone. 2011 , 167-195	
26	[Inhaled iloprost, a selective pulmonary vasodilator. Clinical evidence from its use in perioperative pulmonary hypertension cardiovascular surgery]. 2015 , 85, 136-44	1
25	[Pulmonary arterial hypertension associated to human immunodeficiency virus]. 2015, 85, 118-23	
24	Support Care for the Pulmonary Hypertension Patient. 2016 , 327-343	
23	Antisense oligonucleotides for the arterial hypertension mechanisms study and therapy. 2018 , 22, 240-247	
22	Investigation of the Presence of Sildenafil in Herbal Dietary Supplements by Validated HPLC Method. 2020 , 17, 56-62	1
21	[The place of riociguat in the treatment of patients with pulmonary arterial hypertension associated with systemic connective tissue diseases]. 2020 , 60, 92-101	
20	A Case of Recurrent Lobar Intracerebral Hemorrhage in the Setting of Phosphodiesterase-5 Inhibitor Use. 2019 , 116, 400-403	
19	Pulmonary Arterial Hypertension in Patients Infected with the Human Immunodeficiency Virus. 2022 , 40, 45-54	1
18	Prevalence and risk factors of erectile dysfunction in patients with liver cirrhosis: a systematic review and meta-analysis. 2021 , 1	O

CITATION REPORT

17	2020 Clinical practice guidelines for Pulmonary hypertension, including chronic thromboembolic pulmonary hypertension. 2022 , 26, 4683	9
16	Critical care management of the patient with pulmonary hypertension 2021,	O
15	Pharmacotherapy in Bronchopulmonary Dysplasia: What Is the Evidence?. 2022, 10, 820259	2
14	Antenatal Management of Congenital Diaphragmatic Hernia: what d next?. 2022,	O
13	Pharmacology Management in Improving Exercise Capacity of Patients with Fontan Circulation: A Systematic Review and Meta-Analysis 2022 ,	O
12	Overcoming Therapy Resistance in Colon Cancer by Drug Repurposing 2022, 14,	3
11	Effects of Erectile Dysfunction Drugs Use on T-Cells and Immune Markers on Men Who Have Sex with Men. 1-12	
10	Differential Pulse Voltammetric Determination of Sildenafil Using Nano-Iron Oxides Modified Electrode. 2022 , 24,	1
9	Cognitive Response to Nitric Oxide on Aging People. 2022 ,	
8	Comparison of the effects of Bosentan and Sildenafil in treatment of Patent ductus arteriosus and pulmonary arterial hypertension in preterm infants: A randomized clinical trial	
7	Pulmonary Hypertension in SclerodermalEvaluation and Management. 2022, 101468	О
6	Pulmonary hypertension associated with cardiopulmonary bypass and cardiac surgery.	О
5	Bioinformatic Exploration of Hub Genes and Potential Therapeutic Drugs for Endothelial Dysfunction in Hypoxic Pulmonary Hypertension. 2022 , 2022, 1-17	0
4	Effects of Systemic Drugs on the Development and Progression of Age-Related Macular Degeneration. 2023 ,	O
3	Theranostic applications of nanoemulsions in pulmonary diseases. 2023, 177-216	0
2	Histone deacetylase inhibitors synergize with sildenafil to suppress purine metabolism and proliferation in pulmonary hypertension. 2023 , 149, 107157	О
1	The association of genetically proxied sildenafil with fertility, sexual activity, and wellbeing: a Mendelian randomisation study.	O